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BACKGROUND
Diabetes confers an increased risk of adverse cardiovascular and renal events. In 
the EMPA-REG OUTCOME trial, empagliflozin, a sodium–glucose cotransporter 2 
inhibitor, reduced the risk of major adverse cardiovascular events in patients with 
type 2 diabetes at high risk for cardiovascular events. We wanted to determine the 
long-term renal effects of empagliflozin, an analysis that was a prespecified com-
ponent of the secondary microvascular outcome of that trial.
METHODS
We randomly assigned patients with type 2 diabetes and an estimated glomerular 
filtration rate of at least 30 ml per minute per 1.73 m2 of body-surface area to 
receive either empagliflozin (at a dose of 10 mg or 25 mg) or placebo once daily. 
Prespecified renal outcomes included incident or worsening nephropathy (progres-
sion to macroalbuminuria, doubling of the serum creatinine level, initiation of 
renal-replacement therapy, or death from renal disease) and incident albuminuria.
RESULTS
Incident or worsening nephropathy occurred in 525 of 4124 patients (12.7%) in the 
empagliflozin group and in 388 of 2061 (18.8%) in the placebo group (hazard 
ratio in the empagliflozin group, 0.61; 95% confidence interval, 0.53 to 0.70; 
P<0.001). Doubling of the serum creatinine level occurred in 70 of 4645 patients 
(1.5%) in the empagliflozin group and in 60 of 2323 (2.6%) in the placebo group, 
a significant relative risk reduction of 44%. Renal-replacement therapy was initi-
ated in 13 of 4687 patients (0.3%) in the empagliflozin group and in 14 of 2333 
patients (0.6%) in the placebo group, representing a 55% lower relative risk in the 
empagliflozin group. There was no significant between-group difference in the 
rate of incident albuminuria. The adverse-event profile of empagliflozin in patients 
with impaired kidney function at baseline was similar to that reported in the 
overall trial population.
CONCLUSIONS
In patients with type 2 diabetes at high cardiovascular risk, empagliflozin was 
associated with slower progression of kidney disease and lower rates of clinically 
relevant renal events than was placebo when added to standard care. (Funded by the 
Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance; EMPA-REG 
OUTCOME ClinicalTrials.gov number, NCT01131676.)
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Type 2 diabetes is a major risk factor for macrovascular and microvascular dis-ease.1 Kidney disease develops in approxi-
mately 35% of patients with type 2 diabetes2 and 
is associated with increased mortality.3 Intensive 
glucose-lowering strategies have been shown to 
reduce surrogate markers of renal complications 
in patients with type 2 diabetes; however, evi-
dence for improvement in advanced renal com-
plications is limited.4-8 Thus, despite optimized 
glucose control and the use of single-agent 
blockade of the renin–angiotensin–aldosterone 
system (RAAS), patients with type 2 diabetes 
remain at increased risk for death and complica-
tions from cardiorenal causes.9,10
Empagliflozin, a selective sodium–glucose co-
transporter 2 inhibitor, reduces hyperglycemia 
in patients with type 2 diabetes by reducing the 
renal reabsorption of glucose, thereby increasing 
urinary glucose excretion.11 The use of empa-
gliflozin has been associated with a lowering of 
glycated hemoglobin levels in patients with 
type 2 diabetes, including those with stage 2 or 
3a chronic kidney disease, and with reductions 
in weight and blood pressure, without increases 
in heart rate.12-19 Empagliflozin has been shown 
to reduce intraglomerular pressure and improve 
hyperfiltration in patients with type 1 diabetes,20,21 
and it has been suggested that these effects may 
translate into improved renal outcomes.22 How-
ever, concern has been raised that sodium–glucose 
cotransporter 2 inhibitors may be associated 
with long-term adverse renal effects.
In the recent EMPA-REG OUTCOME trial,23 
the primary goal was to assess cardiovascular 
outcomes. Here we report the results of a pre-
specified secondary objective of that trial, which 
was to examine the effects of empagliflozin on 
microvascular outcomes and, in particular, pro-
gression of kidney disease in patients with type 
2 diabetes at high risk for cardiovascular events.
Me thods
Trial Design and Oversight
The design and methods of the EMPA-REG 
OUTCOME trial have been described previous-
ly.24 In addition, the trial protocol is available 
with the full text of this article at NEJM.org. 
Briefly, the study population included patients 
who had type 2 diabetes, established cardiovas-
cular disease, and an estimated glomerular filtra-
tion rate (eGFR) of at least 30 ml per minute per 
1.73 m2 of body-surface area, according to the 
four-variable Modification of Diet in Renal Dis-
ease (MDRD) formula. Patients were randomly 
assigned to receive either empagliflozin (at a dose 
of 10 mg or 25 mg) or placebo once daily in ad-
dition to standard care.
All the authors were involved in the trial de-
sign and had access to the data, which were 
gathered and analyzed by Boehringer Ingelheim, 
one of the trial sponsors. Medical writing assis-
tance was provided by FleishmanHillard Fishburn, 
with funding from Boehringer Ingelheim. All the 
authors vouch for the accuracy and completeness 
of the data analyses and for the fidelity of the 
trial to the protocol. The first and fifth authors 
wrote the first draft of the manuscript. All the 
authors submitted revisions and made the deci-
sion to submit the manuscript for publication.
Primary and Key Secondary Cardiovascular 
Outcomes
The primary outcome of the EMPA-REG OUT-
COME trial was a composite of three major 
adverse cardiovascular events (3-point MACE), 
which was defined as the first occurrence of 
death from cardiovascular causes, nonfatal myo-
cardial infarction, or nonfatal stroke. The key 
secondary outcome was a composite of the pri-
mary outcome plus hospitalization for unstable 
angina (4-point MACE).
Microvascular and Renal Outcomes
A secondary outcome of the EMPA-REG OUT-
COME trial was a composite microvascular out-
come that included the first occurrence of any of 
the following: the initiation of retinal photo-
coagulation, vitreous hemorrhage, diabetes-related 
blindness, or incident or worsening nephropa-
thy. In this report, we focus on the results of the 
renal microvascular outcomes, as prespecified in 
the statistical analysis plan (available at NEJM.org). 
The first renal microvascular outcome was inci-
dent or worsening nephropathy, defined as pro-
gression to macroalbuminuria (urinary albumin-
to-creatinine ratio, >300 mg of albumin per gram 
of creatinine); a doubling of the serum creati-
nine level, accompanied by an eGFR of ≤45 ml 
per minute per 1.73 m2, as calculated by the 
MDRD formula; the initiation of renal-replace-
ment therapy; or death from renal disease. 
Other prespecified renal microvascular outcomes 
were a composite of incident or worsening ne-
phropathy or death from cardiovascular causes, 
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the individual components of incident or wors-
ening nephropathy, and incident albuminuria 
(urinary albumin-to-creatinine ratio, ≥30) in 
patients with a normal albumin level (urinary 
albumin-to-creatinine ratio, <30) at baseline.
We conducted post hoc analyses in a sub-
group of patients with prevalent kidney disease 
(defined as an eGFR of 59 ml per minute per 
1.73 m2 or less, as calculated by the MDRD for-
mula, or macroalbuminuria) at baseline. In ad-
dition, we performed post hoc analyses of a 
composite of a doubling of the serum creatinine 
level, the initiation of renal-replacement therapy, 
or death from renal disease.
Safety and Laboratory Assessments
We performed assessments of safety and adverse-
event profiles, as described previously.24 We 
evaluated the incidence of acute renal failure 
using the narrow standardized Medical Dictionary 
for Regulatory Activities (MedDRA) query, which 
included the preferred term acute kidney injury. 
We also evaluated the incidence of hyperkalemia 
using two MedDRA preferred terms (hyperkale-
mia and increased blood potassium). Serum 
creatinine and urinary albumin in spot urine 
samples obtained during regular study visits 
were measured in central laboratories with the 
use of standardized procedures. Events that were 
consistent with changes in the albuminuria cat-
egory were captured if any laboratory assess-
ment during the trial fulfilled the given criteria 
on one occasion. We used the MDRD formula to 
assess the eGFR at baseline.25 For prespecified 
assessments of renal function over time, we 
used the creatinine equation developed by the 
Chronic Kidney Disease Epidemiology Collabo-
ration (CKD-EPI).26
Statistical Analysis
We used a modified intention-to-treat approach 
to perform analyses in patients who had re-
ceived at least one dose of a study drug. All 
analyses were performed at the nominal alpha 
level of 0.05 without correction for multiple hy-
pothesis testing. No formal power calculations 
were performed a priori for microvascular out-
comes. The trial protocol specified that the 
outcomes of incident or worsening nephropathy 
(and incident or worsening nephropathy or car-
diovascular death) would be analyzed in treated 
patients who did not have macroalbuminuria at 
baseline, who had available measurements of 
serum creatinine at baseline and after baseline, 
and who had postbaseline measurements of the 
urinary albumin-to-creatinine ratio (unless pa-
tients who did not fulfill these criteria had at 
least one of the other components of the com-
posite renal outcome). A post hoc sensitivity 
analysis included all treated patients. Data from 
patients who did not have an event were cen-
sored on the last day they were known to be free 
of the outcome.
We used a Cox proportional-hazards model to 
assess between-group differences in the risk of 
an outcome after adjustment for study group, age, 
sex, baseline body-mass index, baseline glycated 
hemoglobin level, baseline eGFR, and region. 
We also performed subgroup analyses that in-
cluded additional factors for subgroup and for 
interaction between the study group and sub-
group. Prespecified analyses included compari-
sons of the pooled empagliflozin doses (10 mg 
and 25 mg) and the individual doses versus pla-
cebo. A mixed-model, repeated-measures analy-
sis was used to evaluate changes in the eGFR 
over time and included the glycated hemoglobin 
level and eGFR (according to CKD-EPI criteria) at 
baseline as linear covariates and region, baseline 
body-mass index, the last week a patient could 
have had an eGFR measurement, study group, 
visit, interaction between visit and study group, 
interaction between the baseline glycated hemo-
globin level and visit, and interaction between 
the baseline eGFR and visit as fixed effects. We 
used a random-intercept and time-coefficient 
model to assess differences between the study 
groups in the average rate of change in the eGFR 
for prespecified time periods, with study group, 
baseline body-mass index, and region as fixed 
classification effects and baseline glycated hemo-
globin level, time, and interaction between the 
study group and time as linear covariates. Inter-
cepts and slopes over time were allowed to vary 
randomly between patients by including the pa-
tient and time as random effects.
R esult s
Patients
A total of 7020 patients at 590 sites in 42 coun-
tries received at least one dose of a study drug. 
According to the trial design, more than 99% of 
the patients had established cardiovascular dis-
ease. At baseline, the eGFR was 45 to 59 ml per 
minute per 1.73 m2 in 17.8% of the patients and 
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30 to 44 ml per minute per 1.73 m2 in 7.7%; 
28.7% had microalbuminuria, and 11.0% had 
macroalbuminuria. In total, 80.7% of the patients 
were taking angiotensin-converting–enzyme in-
hibitors or angiotensin-receptor blockers at base-
line. The patients were categorized according to 
whether the eGFR was 60 ml per minute per 
1.73 m2 or more or 59 ml per minute per 1.73 m2 
or less at baseline. The baseline characteristics 
of the patients were generally similar in the two 
study groups (Table 1; and Table S1 in the Sup-
plementary Appendix, available at NEJM.org). A 
higher percentage of patients in the placebo 
group received additional cardiovascular medica-
tions during the trial (Table S2 in the Supple-
mentary Appendix). The median duration of 
treatment was 2.6 years, and the median obser-
vation time was 3.1 years.
Cardiovascular Outcomes
The primary outcome that was reported previ-
ously showed a significantly lower risk of 3-point 
MACE in the pooled empagliflozin group than 
in the placebo group, a difference that was 
driven by a lower rate of death from cardiovas-
cular causes.23 Prespecified secondary and addi-
tional cardiovascular outcomes that were re-
ported previously included the 4-point MACE 
(and components of this composite outcome), 
hospitalization for heart failure, and death from 
any cause.23
Microvascular Outcome
The prespecified composite microvascular out-
come in the overall trial population occurred in 
577 of 4132 patients (14.0%) in the empa-
glif lozin group and in 424 of 2068 patients 
(20.5%) in the placebo group, a significant rela-
tive risk reduction of 38% (Table S3 in the Sup-
plementary Appendix). Because the overall result 
for this composite microvascular outcome was 
driven entirely by the renal component, we have 
focused on renal outcomes in this report.
Renal Outcomes
An assessment of renal outcomes was a pre-
specified objective of the trial, and outcomes 
were defined in a secondary statistical analysis 
plan. Incident or worsening nephropathy oc-
curred in 525 of 4124 patients (12.7%) in the 
empagliflozin group and in 388 of 2061 patients 
(18.8%) in the placebo group, a significant rela-
tive risk reduction of 39% (Fig. 1A and Fig. 2). A 
consistent benefit of empaglif lozin was seen 
across prespecified subgroups (Fig. S1 in the 
Supplementary Appendix) and across the two 
doses of empagliflozin (Fig. S2 in the Supple-
mentary Appendix).
The composite outcome of incident or wors-
ening nephropathy or cardiovascular death was 
significantly lower in the empagliflozin group 
than in the placebo group (Fig. 2, and Fig. S3A in 
the Supplementary Appendix). Equivalent results 
were seen across the two doses of empagliflozin 
(Fig. S3B in the Supplementary Appendix).
Progression to macroalbuminuria occurred in 
459 of 4091 patients (11.2%) in the empa-
gliflozin group and in 330 of 2033 (16.2%) in the 
placebo group, a significant relative risk reduc-
tion of 38% (Fig. 2). A doubling of the serum 
creatinine level occurred in 70 of 4645 patients 
(1.5%) in the empagliflozin group and in 60 of 
2323 (2.6%) in the placebo group, a significant 
relative risk reduction of 44%. The initiation of 
renal-replacement therapy occurred in 13 of 4687 
patients (0.3%) in the empagliflozin group and 
in 14 of 2333 (0.6%) in the placebo group, a 
significant relative risk reduction of 55%. There 
were three deaths from renal disease in the em-
pagliflozin group (0.1%) and none in the placebo 
group. There was no significant between-group 
difference in the rate of incident albuminuria, 
which occurred in 1430 of 2779 patients (51.5%) 
in the empagliflozin group and in 703 of 1374 
(51.2%) in the placebo group (Fig. 2).
Post Hoc Assessments of Renal Outcomes
Results for the composite renal outcomes were 
validated in a post hoc sensitivity analysis (Table 
S4 in the Supplementary Appendix) and in a sub-
group analysis of patients with prevalent kidney 
disease at baseline (Table S5 and Fig. S4 in the 
Supplementary Appendix). The effect of empa-
gliflozin was consistent in further analyses in 
which progression to macroalbuminuria was ex-
cluded from the composite renal outcome (Fig. 1B 
and Fig. 2) with no heterogeneity among sub-
groups of patients with a normal albumin level 
or microalbuminuria or macroalbuminuria at base-
line and in subgroups according to the eGFR at 
baseline (Figs. S5 and S6 in the Supplementary 
Appendix).
Renal Function over Time
Renal function over time, as measured by the 
eGFR, is shown in Fig. 3A. Similar patterns in 
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Characteristic
Patients with eGFR of 59 ml per 
Minute per 1.73 m2 or Less
Patients with eGFR of 60 ml per 
Minute per 1.73 m2 or More
Placebo  
(N = 607)
Empagliflozin 
(N = 1212)
Placebo  
(N = 1726)
Empagliflozin 
(N = 3473)
Age — yr 67.1±8.2 67.1±7.6 61.9±8.6 61.7±8.5
Male sex — no. (%) 418 (68.9) 816 (67.3) 1262 (73.1) 2518 (72.5)
Body-mass index† 30.9±5.4 31.0±5.5 30.6±5.2 30.5±5.2
Glycated hemoglobin — %‡  8.03±0.85  8.07±0.86  8.10±0.84  8.07±0.84
Interval of >10 yr since diagnosis of type 2 diabetes — no. (%) 422 (69.5) 794 (65.5) 917 (53.1) 1876 (54.0)
Blood pressure — mm Hg
Systolic 136.4±18.7 136.1±18.0 135.6±16.7 135.0±16.6
Diastolic 74.6±10.3 74.5±9.9 77.6±10.0 77.4±9.5
Estimated glomerular filtration rate — ml/min/1.73 m2 48.6±7.8 48.4±8.2 82.7±16.6 83.1±17.1
Urinary albumin-to-creatinine ratio — no. (%)§
<30 283 (46.6) 566 (46.7) 1099 (63.7) 2223 (64.0)
30 to 300 205 (33.8) 411 (33.9) 470 (27.2) 926 (26.7)
>300 115 (18.9) 223 (18.4) 145 (8.4) 286 (8.2)
Cholesterol — mg/dl
Low-density lipoprotein¶ 85.0±36.1 84.4±35.8 84.8±35.1 86.5±36.0
High-density lipoprotein‖ 42.9±10.7 44.2±12.5 44.4±11.5 44.7±11.7
Triglycerides — mg/dl‖ 180.4±107.4 173.5±108.1 167.2±125.6 169.4±136.4
Coronary artery disease 482 (79.4) 938 (77.4) 1281 (74.2) 2606 (75.0)
History of stroke** 156 (25.7) 293 (24.2) 397 (23.0) 791 (22.8)
Peripheral artery disease†† 130 (21.4) 314 (25.9) 349 (20.2) 667 (19.2)
Cardiac failure‡‡ 89 (14.7) 174 (14.4) 155 (9.0) 288 (8.3)
Concomitant medication — no. (%)
Angiotensin-converting–enzyme inhibitor or angiotensin-
receptor blocker
502 (82.7) 1031 (85.1) 1366 (79.1) 2766 (79.6)
Beta-blocker 415 (68.4) 829 (68.4) 1083 (62.7) 2226 (64.1)
Diuretic 355 (58.5) 710 (58.6) 633 (36.7) 1336 (38.5)
Calcium-channel blocker 227 (37.4) 446 (36.8) 561 (32.5) 1082 (31.2)
Statin 461 (75.9) 966 (79.7) 1312 (76.0) 2663 (76.7)
Aspirin 495 (81.5) 981 (80.9) 1432 (83.0) 2894 (83.3)
Metformin 369 (60.8) 711 (58.7) 1365 (79.1) 2746 (79.1)
Sulfonylurea 234 (38.6) 480 (39.6) 758 (43.9) 1534 (44.2)
Insulin 357 (58.8) 699 (57.7) 778 (45.1) 1551 (44.7)
*  Plus–minus values are means ±SD. The GFR at baseline was estimated according to the four-variable Modification of Diet in Renal Disease 
formula. Data on eGFR at baseline were not available for two patients in the empagliflozin group. There were no significant differences be-
tween the study groups except with respect to high-density lipoprotein cholesterol (P = 0.02) and peripheral artery disease (P = 0.04) in pa-
tients with an eGFR of 59 ml per minute per 1.73 m2 or less. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. 
To convert the values for triglycerides to millimoles per liter, multiply by 0.01129.
†  The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡  The glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an eGFR of 60 ml per minute per 
1.73 m2 or more.
§  This ratio was measured in milligrams of albumin per grams of creatinine.
¶  Low-density lipoprotein cholesterol was measured in 598 patients in the placebo group and 1201 in the empagliflozin group in patients 
with an eGFR of 59 ml per minute per 1.73 m2 or less and in 1711 patients in the placebo group and 3421 in the empagliflozin group in 
patients with an eGFR of 60 ml per minute per 1.73 m2 or more.
‖  High-density lipoprotein cholesterol and triglycerides were measured in 598 patients in the placebo group and 1202 in the empagliflozin 
group in patients with an eGFR of 59 ml per minute per 1.73 m2 or less and in 1711 patients in the placebo group and 3423 in the empa-
gliflozin group in patients with an eGFR of 60 ml per minute per 1.73 m2 or more.
**  Information on stroke history was not available for one patient in the placebo group in patients with an eGFR of 60 ml per minute per  
1.73 m2 or more.
††  Information on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group 
in patients with an eGFR of 60 ml per minute per 1.73 m2 or more.
‡‡  Cardiac failure was determined according to the narrow standardized Medical Dictionary for Regulatory Activities query for the condition.
Table 1. Characteristics of the Patients at Baseline, According to the Estimated Glomerular Filtration Rate (eGFR).*
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the eGFR were observed in patients with an 
eGFR of 60 ml per minute per 1.73 m2 or more 
and in patients with an eGFR of 59 ml per minute 
per 1.73 m2 or less at baseline (Fig. S7 in the Sup-
plementary Appendix). The initial decrease in 
the eGFR in the empagliflozin group was com-
pletely reversed after the cessation of the study 
drug (Fig. 3B). At the follow-up visit, the ad-
justed mean difference from placebo in the 
change from baseline in the eGFR with each of 
the two doses of empagliflozin was 4.7 ml per 
minute per 1.73 m2 (95% confidence interval, 4.0 
to 5.5; P<0.001 for both comparisons) (Fig. 3B).
We quantified the difference between the 
study groups in the average rate of change in the 
eGFR for three prespecified time periods, using 
the CKD-EPI creatinine equation. From baseline 
to week 4 (period 1), there was a short-term de-
crease in the eGFR in the empagliflozin groups, 
with mean (±SE) adjusted estimates of weekly 
decreases of 0.62±0.04 ml per minute per 1.73 m2 
in the 10-mg group and 0.82±0.04 ml per min-
ute per 1.73 m2 in the 25-mg group, as compared 
with a small increase (of 0.01±0.04 ml per min-
ute per 1.73 m2) in the placebo group (P<0.001 
for both comparisons with placebo). Thereafter, 
during long-term administration (period 2; from 
week 4 to the last week of treatment), the eGFR 
remained stable in the empagliflozin groups and 
declined steadily in the placebo group, with ad-
justed estimates of annual decreases of 0.19±0.11 
ml per minute per 1.73 m2 in the 10-mg and 
25-mg empagliflozin groups, as compared with a 
decrease of 1.67±0.13 ml per minute per 1.73 m2 
in the placebo group (P<0.001 for both com-
parisons with placebo). After the cessation of 
the study drug (period 3; last week of treatment 
to follow-up), the eGFR increased with both 
doses of empagliflozin, with adjusted estimates 
for weekly increases of 0.48±0.04 ml per minute 
per 1.73 m2 in the 10-mg group and 0.55±0.04 
ml per minute per 1.73 m2 in the 25-mg group, 
as compared with a small decrease (of 0.04±0.04 
ml per minute per 1.73 m2) in the placebo group 
(P<0.001 for both comparisons with placebo).
Safety and Adverse Events
The percentages of patients who had an adverse 
event, a serious adverse event, or an adverse 
event leading to study-drug discontinuation were 
similar in the empagliflozin group and the pla-
cebo group in patients with an eGFR of 60 ml 
per minute per 1.73 m2 or more and in patients 
with an eGFR of 59 ml per minute per 1.73 m2 
or less (Table 2, and Table S6 and Fig. S8 in the 
Supplementary Appendix). Genital infections 
were reported in a higher percentage of patients 
in the empagliflozin group than in the placebo 
group. There were similar rates of overall uri-
nary tract infection, complicated urinary tract 
infection, and pyelonephritis in the two study 
groups. Urosepsis was reported infrequently, but 
the proportion of patients with events was 
higher with empaglif lozin than with placebo 
(Table S7 in the Supplementary Appendix). The 
percentages of patients with confirmed hypogly-
cemic episodes, diabetic ketoacidosis, thrombo-
embolic events, bone fractures, and events con-
sistent with volume depletion were similar in the 
two study groups. Events that were consistent 
with acute renal failure, including acute kidney 
injury, and hyperkalemia were reported in a 
lower percentage of patients in the empagliflozin 
group than in the placebo group (Figs. S8 and 
S9 in the Supplementary Appendix). Clinical 
laboratory measurements are provided in Table 
S8 in the Supplementary Appendix.
Discussion
In patients with type 2 diabetes at high risk for 
cardiovascular events, those who received empa-
gliflozin in addition to standard care had a sig-
nificantly lower risk of microvascular outcome 
events than did those receiving placebo, a differ-
ence that was driven by a lower risk of progres-
sion of kidney disease (as defined by incident or 
worsening nephropathy). Patients in the empa-
gliflozin group also had a significantly lower 
risk of progression to macroalbuminuria or clini-
cally relevant renal outcomes, such as a doubling 
of the serum creatinine level and initiation of 
renal-replacement therapy, than did those in the 
placebo group.
The magnitude of the renal effect associated 
with empagliflozin was consistent with respect 
to the competing risk of death from cardiovas-
cular causes, as well as between empagliflozin 
doses of 10 mg and 25 mg and across prespeci-
fied subgroups, including patients with preva-
lent kidney disease. These results were observed 
in a population of patients whose blood pressure 
was well managed, with extensive use of RAAS 
blockers, the recommended treatment for kidney 
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disease in patients with type 2 diabetes. How-
ever, the renal effects of empagliflozin cannot 
necessarily be generalized to patients with type 
2 diabetes at lower cardiovascular risk. General-
ization of the findings to black patients also has 
limitations because of the small sample size that 
we studied. Further clinical research is war-
ranted to validate our findings in broader popu-
lations at risk for adverse renal outcomes.
Empagliflozin was associated with lower rates 
of hyperglycemia and lower values for weight 
and blood pressure than was placebo.23 A trial 
comparing an intensive multifactorial interven-
tion with conventional therapy in patients with 
type 2 diabetes and microalbuminuria did not 
show significant differences in the decline in 
renal function after 7.8 years.27 Thus, in our trial, 
the magnitude of the observed effect on these 
risk factors over a median follow-up period of 
3.1 years is unlikely to fully account for the ob-
served difference in renal function among pa-
tients receiving empagliflozin.
The mechanisms behind the renal effects of 
empaglif lozin are probably multifactorial, but 
direct renovascular effects may play an impor-
tant role.21,28,29 Empagliflozin reduces proximal 
tubular sodium reabsorption, thereby increasing 
distal sodium delivery to the macula densa, 
which has been shown to activate tubuloglo-
merular feedback, leading to afferent vasomodu-
lation and a decrease in hyperfiltration.30 In pa-
tients with type 1 diabetes and hyperfiltration, 
empagliflozin reduces the intraglomerular pres-
sure.20 Despite the low-pressure environment of 
renal glomeruli, a reduction in glomerular hy-
pertension of approximately 6 to 8 mm Hg was 
observed with empagliflozin.20 Other effects, 
such as those on arterial stiffness,28,29 vascular 
resistance,28 serum uric acid levels,23 and the 
systemic and renal neurohormonal systems,29,31,32 
may also contribute to the improvements in the 
progression of renal disease observed with em-
pagliflozin. Further research is needed to ex-
plore whether empagliflozin-associated changes 
in blood volume or renal perfusion may alter 
serum creatinine turnover and renal-function 
assessments.
Previous trials have focused on the role of 
RAAS blockade for improving renal outcomes in 
type 2 diabetes.33-35 Such blockade causes vasodi-
lation of the efferent arteriolar system of the 
glomerulus and a reduction in intraglomerular 
pressure.36,37 This vasomodulatory mechanism is 
known to cause a short-term decrease in the 
eGFR,38 which is accompanied by a smaller de-
cline in renal function during continued treat-
ment.39 In our trial, empaglif lozin showed a 
similar pattern of change in renal function (i.e., 
a short-term decrease followed by stabilization 
Figure 1. Kaplan–Meier Analysis of Two Key Renal Outcomes.
Shown are estimates of the probability of a first occurrence of a prespecified 
renal composite outcome of incident or worsening nephropathy (Panel A) 
and of a post hoc renal composite outcome (a doubling of the serum creat-
inine level, the initiation of renal-replacement therapy, or death from renal 
disease) (Panel B) among patients who received at least one dose of either 
empagliflozin or placebo. The inset in Panel B shows the data on an expand-
ed y axis. Hazard ratios are based on Cox regression analyses. Because of 
the declining numbers of patients at risk, Kaplan–Meier curves have been 
truncated at 48 months.
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Figure 3. Renal Function over Time.
Shown are the adjusted means for the estimated glomerular filtration rate (eGFR) over a period of 192 weeks (Panel A) 
and at the last measurement during treatment and at follow-up (Panel B) among patients who received empagliflozin 
(at a dose of 10 mg or 25 mg) or placebo. Baseline values are means, and the I bars indicate standard errors. The eGFR 
was calculated according to the creatinine formula developed by the Chronic Kidney Disease Epidemiology Collaboration. 
Among patients in the empagliflozin group, the adjusted mean difference from placebo in the change from baseline at 
follow-up (Panel B) was 4.7 ml per minute per 1.73 m2 in both the 10-mg and 25-mg groups (P<0.001 for both compari-
sons). Panel A is based on prespecified mixed-model, repeated-measures analysis in patients who received at least one 
dose of a study drug and had a baseline and postbaseline measurement. Panel B is based on a prespecified analysis of 
a covariance model (with the baseline eGFR and glycated hemoglobin level as linear covariates and baseline body-mass 
index, region, and study group as fixed effects) in patients who underwent measurements at all three time points.
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in the eGFR over time). Moreover, measures of 
renal function significantly improved after the 
discontinuation of empagliflozin, indicating that 
glomerular hemodynamic changes were reversed 
even after long-term treatment. Most patients in 
this trial were receiving background RAAS 
blockade, so the renal effects of empagliflozin 
were still apparent even with the use of these 
Event
Patients with Baseline eGFR of 59 ml per Minute  
per 1.73 m2 or Less
Patients with Baseline eGFR of 60 ml per Minute  
per 1.73 m2 or More
Placebo 
(N= 607)
Empagliflozin 
(N = 1212)
Placebo 
(N = 1726)
Empagliflozin 
(N = 3473)
no. (%)
rate per 100 
patient-yr no. (%)
rate per 100 
patient-yr no. (%)
rate per 100 
patient-yr no. (%)
rate per 100 
patient-yr
Any adverse event 577 (95.1) 262.3 1107 (91.3) 183.4 1562 (90.5) 159.8 3121 (89.9) 140.1
Severe adverse event† 208 (34.3) 17.3  360 (29.7) 14.0  384 (22.2) 9.9  740 (21.3) 9.1
Serious adverse event† 321 (52.9) 31.7  552 (45.5) 24.9  667 (38.6) 19.6 1237 (35.6) 17.0
Death 40 (6.6) 2.8  68 (5.6) 2.3  79 (4.6) 1.8 108 (3.1) 1.2
Adverse event leading to 
 discontinuation
167 (27.5) 12.6  278 (22.9) 10.0  286 (16.6) 6.9  535 (15.4) 6.2
Confirmed hypoglycemic 
 adverse event‡
Any 233 (38.4) 22.9 391 (32.3) 17.9 417 (24.2) 11.7 912 (26.3) 12.8
Requiring assistance 18 (3.0) 1.3 23 (1.9) 0.8 18 (1.0) 0.4 40 (1.2) 0.4
Event consistent with urinary 
tract infection
Any§ 132 (21.7) 10.4 278 (22.9) 11.0 291 (16.9) 7.5  564 (16.2) 6.9
Complicated ¶ 17 (2.8) 1.2 37 (3.1) 1.3 24 (1.4) 0.6  45 (1.3) 0.5
Event consistent with genital 
infection‖
10 (1.6) 0.7 64 (5.3) 2.2 32 (1.9) 0.7 237 (6.8) 2.7
Event consistent with vol-
ume depletion**
49 (8.1) 3.6 81 (6.7) 2.8 66 (3.8) 1.6 158 (4.5) 1.8
Acute renal failure††  87 (14.3) 6.5 136 (11.2) 4.9 68 (3.9) 1.6 110 (3.2) 1.2
Acute kidney injury 22 (3.6) 1.6 26 (2.1) 0.9 15 (0.9) 0.4  19 (0.5) 0.2
Diabetic ketoacidosis‡‡  1 (0.2) 0.1  2 (0.2) 0.1 0 0   2 (0.1) <0.1
Thromboembolic event§§  7 (1.2) 0.5 13 (1.1) 0.4 13 (0.8) 0.3  17 (0.5) 0.2
Bone fracture¶¶ 32 (5.3) 2.3 57 (4.7) 2.0 59 (3.4) 1.4 122 (3.5) 1.4
Hyperkalemia‖‖ 42 (6.9) 3.0 47 (3.9) 1.6 36 (2.1) 0.8  46 (1.3) 0.5
*  Data are for patients who received at least one dose of a study drug and include events that occurred during treatment or within 7 days 
 after the last receipt of a study drug.
†  A serious adverse event is defined as an event that is fatal or life-threatening, results in persistent or significant disability, requires or pro-
longs hospitalization, is associated with a congenital anomaly or birth defect, or is deemed to be serious for any other reason. A severe 
adverse event is one that is incapacitating or that results in an inability to work or perform usual activities.
‡  Hypoglycemia was defined as a plasma glucose level of 70 mg per deciliter (3.9 mmol per liter) or less or an event requiring assistance.
§  The definition of urinary tract infection was based on 79 preferred terms in the Medical Dictionary for Regulatory Activities (MedDRA).
¶  Complicated urinary tract infection comprised pyelonephritis, urosepsis, and a serious adverse event consistent with urinary tract infection.
‖  The definition of genital infection was based on 88 MedDRA preferred terms.
**  The definition of volume depletion was based on 8 MedDRA preferred terms.
††  The definition of acute renal failure was based on the narrow standardized MedDRA query for the condition.
‡‡  The definition of diabetic ketoacidosis was based on 4 MedDRA preferred terms.
§§  The definition of thromboembolic event was based on 1 standardized MedDRA query.
¶¶  The definition of bone fracture was based on 62 MedDRA preferred terms.
‖‖  The definition of hyperkalemia was based on 2 MedDRA preferred terms.
Table 2. Adverse Events.*
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agents. This finding supports the potential use 
of empagliflozin in combination with RAAS 
blockers in patients with type 2 diabetes and 
chronic kidney disease. However, empagliflozin 
did not prevent incident albuminuria despite 
previous evidence that the drug lowers the intra-
glomerular pressure.20
The adverse-event profile of empagliflozin in 
patients who had impaired kidney function at 
baseline, a potentially vulnerable population, 
was consistent with that reported in the overall 
trial population. The proportion of patients with 
genital infection was greater in the empagliflozin 
group than in the placebo group, which was 
consistent with findings in previous studies. 
Rates of adverse events consistent with acute 
renal failure (including acute kidney injury) or 
hyperkalemia in the empagliflozin group were 
lower than or similar to those in the placebo 
group, regardless of whether patients had im-
paired kidney function at baseline.
In conclusion, among patients with type 2 
diabetes who were at high risk for cardiovascular 
events, the use of empagliflozin was associated 
with slower progression of kidney disease than 
was placebo when added to standard care. Empa-
gliflozin was also associated with a significantly 
lower risk of clinically relevant renal events.
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We thank all the patients who participated in this trial; and 
Elizabeth Ng and Wendy Morris of FleishmanHillard Fishburn 
for their medical writing assistance.
References
1. The Emerging Risk Factors Collabora-
tion. Diabetes mellitus, fasting blood glu-
cose concentration, and risk of vascular 
disease: a collaborative meta-analysis of 
102 prospective studies. Lancet 2010; 375: 
2215-22.
2. de Boer IH, Rue TC, Hall YN, Hea-
gerty PJ, Weiss NS, Himmelfarb J. Tempo-
ral trends in the prevalence of diabetic 
kidney disease in the United States. JAMA 
2011; 305: 2532-9.
3. Afkarian M, Sachs MC, Kestenbaum 
B, et al. Kidney disease and increased 
mortality risk in type 2 diabetes. J Am Soc 
Nephrol 2013; 24: 302-8.
4. UK Prospective Diabetes Study 
 (UKPDS) Group. Intensive blood-glucose 
control with sulphonylureas or insulin 
compared with conventional treatment 
and risk of complications in patients with 
type 2 diabetes (UKPDS 33). Lancet 1998; 
352: 837-53.
5. Coca SG, Ismail-Beigi F, Haq N, 
Krumholz HM, Parikh CR. Role of inten-
sive glucose control in development of 
renal end points in type 2 diabetes melli-
tus: systematic review and meta-analysis 
intensive glucose control in type 2 diabe-
tes. Arch Intern Med 2012; 172: 761-9.
6. The ADVANCE Collaborative Group. 
Intensive blood glucose control and vas-
cular outcomes in patients with type 2 
diabetes. N Engl J Med 2008; 358: 2560-
72.
7. Perkovic V, Heerspink HL, Chalmers J, 
et al. Intensive glucose control improves 
kidney outcomes in patients with type 2 
diabetes. Kidney Int 2013; 83: 517-23.
8. Zoungas S, Chalmers J, Neal B, et al. 
Follow-up of blood-pressure lowering and 
glucose control in type 2 diabetes. N Engl 
J Med 2014; 371: 1392-406.
9. Roscioni SS, Heerspink HJ, de Zeeuw 
D. The effect of RAAS blockade on the 
progression of diabetic nephropathy. Nat 
Rev Nephrol 2014; 10: 77-87.
10. Molitch ME, Adler AI, Flyvbjerg A, et 
al. Diabetic kidney disease: a clinical up-
date from Kidney Disease: Improving 
Global Outcomes. Kidney Int 2015; 87: 20-
30.
11. Heise T, Seewaldt-Becker E, Macha S, 
et al. Safety, tolerability, pharmacokinetics 
and pharmacodynamics following 4 weeks’ 
treatment with empagliflozin once daily 
in patients with type 2 diabetes. Diabetes 
Obes Metab 2013; 15: 613-21.
12. Häring HU, Merker L, Seewaldt-Becker 
E, et al. Empagliflozin as add-on to met-
formin plus sulfonylurea in patients with 
type 2 diabetes: a 24-week, randomized, 
double-blind, placebo-controlled trial. 
Diabetes Care 2013; 36: 3396-404.
13. Häring HU, Merker L, Seewaldt-Becker 
E, et al. Empagliflozin as add-on to met-
formin in patients with type 2 diabetes: 
a 24-week, randomized, double-blind, 
placebo-controlled trial. Diabetes Care 
2014; 37: 1650-9.
14. Kovacs CS, Seshiah V, Swallow R, et al. 
Empagliflozin improves glycaemic and 
weight control as add-on therapy to pio-
glitazone or pioglitazone plus metformin 
in patients with type 2 diabetes: a 24-week, 
randomized, placebo-controlled trial. Dia-
betes Obes Metab 2014; 16: 147-58.
15. Roden M, Weng J, Eilbracht J, et al. 
Empagliflozin monotherapy with sita-
gliptin as an active comparator in patients 
with type 2 diabetes: a randomised, double-
blind, placebo-controlled, phase 3 trial. 
Lancet Diabetes Endocrinol 2013; 1: 208-19.
16. Rosenstock J, Jelaska A, Frappin G, et 
al. Improved glucose control with weight 
loss, lower insulin doses, and no in-
creased hypoglycemia with empagliflozin 
added to titrated multiple daily injections 
of insulin in obese inadequately con-
trolled type 2 diabetes. Diabetes Care 
2014; 37: 1815-23.
17. Rosenstock J, Jelaska A, Zeller C, Kim 
G, Broedl UC, Woerle HJ. Impact of empa-
gliflozin added on to basal insulin in type 2 
diabetes inadequately controlled on basal 
insulin: a 78-week randomized, double-
blind, placebo-controlled trial. Diabetes 
Obes Metab 2015; 17: 936-48.
18. Tikkanen I, Narko K, Zeller C, et al. 
Empagliflozin reduces blood pressure in 
patients with type 2 diabetes and hyper-
tension. Diabetes Care 2015; 38: 420-8.
19. Barnett AH, Mithal A, Manassie J, et al. 
Efficacy and safety of empagliflozin add-
ed to existing antidiabetes treatment in 
patients with type 2 diabetes and chronic 
kidney disease: a randomised, double-
blind, placebo-controlled trial. Lancet 
Diabetes Endocrinol 2014; 2: 369-84.
20. Skrtić M, Yang GK, Perkins BA, et al. 
Characterisation of glomerular haemody-
namic responses to SGLT2 inhibition in 
patients with type 1 diabetes and renal 
hyperfiltration. Diabetologia 2014; 57: 2599-
602.
21. Cherney DZ, Perkins BA, Soleyman-
lou N, et al. Renal hemodynamic effect of 
sodium-glucose cotransporter 2 inhibi-
tion in patients with type 1 diabetes mel-
litus. Circulation 2014; 129: 587-97.
22. Škrtić M, Cherney DZ. Sodium-glu-
cose cotransporter-2 inhibition and the 
potential for renal protection in diabetic 
nephropathy. Curr Opin Nephrol Hyper-
tens 2015; 24: 96-103.
23. Zinman B, Wanner C, Lachin JM, et al. 
Empagliflozin, cardiovascular outcomes, 
and mortality in type 2 diabetes. N Engl J 
Med 2015; 373: 2117-28.
24. Zinman B, Inzucchi SE, Lachin JM, et 
al. Rationale, design, and baseline char-
acteristics of a randomized, placebo-con-
trolled cardiovascular outcome trial of 
The New England Journal of Medicine 
Downloaded from nejm.org at GLASGOW UNIVERSITY LIBRARY on December 9, 2019. For personal use only. No other uses without permission. 
 Copyright © 2016 Massachusetts Medical Society. All rights reserved. 
n engl j med 375;4 nejm.org July 28, 2016334
Empagliflozin and Kidney Disease in Type 2 Diabetes
clinical trial registration
The Journal requires investigators to register their clinical trials  
in a public trials registry. The members of the International Committee  
of Medical Journal Editors (ICMJE) will consider most reports of clinical  
trials for publication only if the trials have been registered.  
Current information on requirements and appropriate registries  
is available at www.icmje.org/faq_clinical.html.
empagliflozin (EMPA-REG OUTCOME). 
Cardiovasc Diabetol 2014; 13: 102.
25. Levey AS, Bosch JP, Lewis JB, Greene 
T, Rogers N, Roth D. A more accurate 
method to estimate glomerular filtration 
rate from serum creatinine: a new predic-
tion equation. Ann Intern Med 1999; 130: 
461-70.
26. Levey AS, Stevens LA, Schmid CH, et al. 
A new equation to estimate glomerular 
filtration rate. Ann Intern Med 2009; 150: 
604-12.
27. Gaede P, Vedel P, Larsen N, Jensen GV, 
Parving HH, Pedersen O. Multifactorial 
intervention and cardiovascular disease 
in patients with type 2 diabetes. N Engl J 
Med 2003; 348: 383-93.
28. Chilton R, Tikkanen I, Cannon CP, et 
al. Effects of empagliflozin on blood 
pressure and markers of arterial stiffness 
and vascular resistance in patients with 
type 2 diabetes. Diabetes Obes Metab 
2015; 17: 1180-93.
29. Cherney DZ, Perkins BA, Soleyman-
lou N, et al. The effect of empagliflozin 
on arterial stiffness and heart rate vari-
ability in subjects with uncomplicated 
type 1 diabetes mellitus. Cardiovasc Dia-
betol 2014; 13: 28.
30. Vallon V, Gerasimova M, Rose MA, et 
al. SGLT2 inhibitor empagliflozin reduc-
es renal growth and albuminuria in pro-
portion to hyperglycemia and prevents 
glomerular hyperfiltration in diabetic Akita 
mice. Am J Physiol Renal Physiol 2014; 
306: F194-204.
31. Cherney DZ, Perkins BA, Soleyman-
lou N, et al. Sodium glucose cotransport-2 
inhibition and intrarenal RAS activity in 
people with type 1 diabetes. Kidney Int 
2014; 86: 1057-8.
32. Jordan J, Tank J, Heusser K, et al. Em-
paglif lozin has no discernable effect on 
muscle sympathetic nerve activity in pa-
tients with type 2 diabetes despite reduc-
tions in blood pressure and weight. Dia-
betes 2014; 63: Suppl 1: A265 (poster).
33. Lewis EJ, Hunsicker LG, Clarke WR, 
et al. Renoprotective effect of the angio-
tensin-receptor antagonist irbesartan in 
patients with nephropathy due to type 2 
diabetes. N Engl J Med 2001; 345: 851- 
60.
34. Brenner BM, Cooper ME, de Zeeuw D, 
et al. Effects of losartan on renal and car-
diovascular outcomes in patients with 
type 2 diabetes and nephropathy. N Engl J 
Med 2001; 345: 861-9.
35. Parving H-H, Brenner BM, McMurray 
JJV, et al. Cardiorenal end points in a trial 
of aliskiren for type 2 diabetes. N Engl J 
Med 2012; 367: 2204-13.
36. Brown NJ, Vaughan DE. Angiotensin-
converting enzyme inhibitors. Circulation 
1998; 97: 1411-20.
37. Kobori H, Nangaku M, Navar LG, 
Nishiyama A. The intrarenal renin-angio-
tensin system: from physiology to the 
pathobiology of hypertension and kid-
ney disease. Pharmacol Rev 2007; 59: 251-
87.
38. Schoolwerth AC, Sica DA, Ballermann 
BJ, Wilcox CS. Renal considerations in 
angiotensin converting enzyme inhibitor 
therapy: a statement for healthcare pro-
fessionals from the Council on the Kidney 
in Cardiovascular Disease and the Coun-
cil for High Blood Pressure Research of 
the American Heart Association. Circula-
tion 2001; 104: 1985-91.
39. Holtkamp FA, de Zeeuw D, Thomas 
MC, et al. An acute fall in estimated glo-
merular filtration rate during treatment 
with losartan predicts a slower decrease 
in long-term renal function. Kidney Int 
2011; 80: 282-7.
Copyright © 2016 Massachusetts Medical Society.
The New England Journal of Medicine 
Downloaded from nejm.org at GLASGOW UNIVERSITY LIBRARY on December 9, 2019. For personal use only. No other uses without permission. 
 Copyright © 2016 Massachusetts Medical Society. All rights reserved. 
